Key Details
Price
$3.57Annual ROE
-44.93%Beta
0.11Events Calendar
Next earnings date:
Mar 5, 2025Recent quarterly earnings:
Nov 5, 2024Recent annual earnings:
Mar 5, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland , Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights.
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Operator Good morning. My name is Nicole [ph] and I will be your conference operator today.
BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO.
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72.5% in the prior year period, respectively Operating loss was $15.4 million on a reported basis and $10.6 million on an adjusted basis, representing year-over-year improvements of 7.1% and 10.4%, respectively Cash burn was $9.6 million, representing a year-over-year improvement of 39.1% The company reiterates full-year guidance, including revenue between $65 million and $67 million, adjusted gross margin of 72.0% to 72.5%, and adjusted operating loss between $45 million and $50 million "Record analysis volume drove a reacceleration of Clinical growth across most key geographies in Q3, with volume increasing 16% year-over-year, offset by expected softness in BioPharma," said Jurgi Camblong, PhD.
BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024.
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.
The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY.
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio.
SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FAQ
- What is the ticker symbol for SOPHiA GENETICS SA?
- Does SOPHiA GENETICS SA pay dividends?
- What sector is SOPHiA GENETICS SA in?
- What industry is SOPHiA GENETICS SA in?
- What country is SOPHiA GENETICS SA based in?
- When did SOPHiA GENETICS SA go public?
- Is SOPHiA GENETICS SA in the S&P 500?
- Is SOPHiA GENETICS SA in the NASDAQ 100?
- Is SOPHiA GENETICS SA in the Dow Jones?
- When was SOPHiA GENETICS SA's last earnings report?
- When does SOPHiA GENETICS SA report earnings?
- Should I buy SOPHiA GENETICS SA stock now?